Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Stein

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|March 23, 1991
Topical calcipotriol treatment in advanced breast cancerM Bower, K W Colston, R C Stein, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trialR C Stein, M Bower, M Law, et al.
Journal of Molecular Biology|March 26, 1998
Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinaseG Siegal, B Davis, S M Kristensen, et al.
British Journal of Cancer|March 1, 1990
Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee studyR C Stein, M Dowsett, D C Cunningham, et al.
Journal of Clinical Pathology|September 25, 2013
HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practiceA M Shaaban, C A Purdie, J M S Bartlett, et al.
British Journal of Cancer|May 30, 2007
Predictors of ovarian reserve in young women with breast cancerK Lutchman Singh, S Muttukrishna, R C Stein, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 30, 2016
Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it rightA Francis, J Bartlett, D Rea, et al.
British Journal of Cancer|February 1, 1991
The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]R C Stein, V Malkovska, S Morgan, et al.
British Journal of Cancer|February 22, 2017
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trialS E Pinder, A F Campbell, J M S Bartlett, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplastiesM J Page, B Amess, R R Townsend, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|March 23, 1991
Topical calcipotriol treatment in advanced breast cancerM Bower, K W Colston, R C Stein, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trialR C Stein, M Bower, M Law, et al.
Journal of Molecular Biology|March 26, 1998
Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinaseG Siegal, B Davis, S M Kristensen, et al.
British Journal of Cancer|March 1, 1990
Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee studyR C Stein, M Dowsett, D C Cunningham, et al.
Journal of Clinical Pathology|September 25, 2013
HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practiceA M Shaaban, C A Purdie, J M S Bartlett, et al.
British Journal of Cancer|May 30, 2007
Predictors of ovarian reserve in young women with breast cancerK Lutchman Singh, S Muttukrishna, R C Stein, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 30, 2016
Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it rightA Francis, J Bartlett, D Rea, et al.
British Journal of Cancer|February 1, 1991
The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]R C Stein, V Malkovska, S Morgan, et al.
British Journal of Cancer|February 22, 2017
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trialS E Pinder, A F Campbell, J M S Bartlett, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplastiesM J Page, B Amess, R R Townsend, et al.
Pageof 5